Peptide-based Immunization for Colon- and and Pancreas-carcinoma (PICOP-GLOBAL)

CENTOGENE

Status: Completed

Conditions: Rectal Adenocarcinoma; Colon Neoplasm; Pancreatic Adenocarcinoma; Colon Cancer; Colo-rectal Cancer; Pancreas Cancer; Rectal Tumors; Rectal Neoplasms; Pancreatic Neoplasms; Pancreatic Cancer; Rectal Cancer; Colon Adenocarcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03871790

PICOP-GLOBAL-2019

Details and patient eligibility

About

An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.

Full description

Colorectal and pancreatic cancers are among the most common causes of cancer-related death over the world. Standard of care treatment for colon and pancreas cancer is stage dependent and includes surgical, chemotherapeutic, and radiation therapy. However, the current statistics underlines an urgent need for improved treatment. Patient-individualized treatments and enhancement of the immune response via vaccination are among new therapeutic options.

The enhancement of the immune response via vaccination is among new therapeutic options. Here, either cell-specific antigens, over-expressed tumor specific antigens or mutated tumor-specific antigens (neoepitopes) can be employed. Especially the latter possess the biggest potential for high specificity but presuppose an extensive characterization of the respective tumor. In order to identify a neoepitope-based vaccination approach for patient-individualized treatment options the molecular particularities of tumors have to be analysed.

The aim of this study is to identify tumor molecular particularities and neoepitopes among patients with colorectal and pancreatic tumors undergoing surgery.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent is obtained from the participant
• Patients with pancreas or colorectal carcinoma undergoing surgery
• The participant is older than 18 years old

Exclusion criteria

• Inability to provide informed consent
• The patient is not suffering from pancreas or colo-rectal carcinoma
• Patient has a condition contradicting surgery
• The participant is younger than 18 years old
• Previously enrolled in the study

Trial design

50 participants in 2 patient groups

Participants with colorectal cancer

Description:

Participants with colorectal cancer ongoing surgery older than 18 years old.

Participants with pancreatic cancer

Description:

Participants with pancreatic cancer ongoing surgery older than 18 years old.